Provided by Tiger Trade Technology Pte. Ltd.

Janux Therapeutics, Inc.

13.27
+0.20001.53%
Post-market: 13.270.00000.00%18:28 EST
Volume:1.17M
Turnover:15.50M
Market Cap:798.16M
PE:-7.90
High:13.45
Open:13.03
Low:12.75
Close:13.07
52wk High:41.56
52wk Low:12.12
Shares:60.15M
Float Shares:44.97M
Volume Ratio:0.67
T/O Rate:2.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6802
EPS(LYR):-1.2836
ROE:-12.48%
ROA:-10.49%
PB:0.82
PE(LYR):-10.34

Loading ...

Janux Therapeutics Files Initial Beneficial Ownership Statement for Chief Medical Officer William Go

Reuters
·
Feb 05

Janux Therapeutics Names William Go as Chief Medical Officer

Reuters
·
Jan 26

Janux Therapeutics Appoints William Go, M.d., Ph.d., as Chief Medical Officer

THOMSON REUTERS
·
Jan 26

Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million

Benzinga
·
Jan 23

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, JPMorgan, Intel

Reuters
·
Jan 23

Janux Therapeutics: Bristol Myers Collaboration Validates Tumor-Activated Platform and Enhances Risk–Reward Profile

TIPRANKS
·
Jan 23

BUZZ-U.S. STOCKS ON THE MOVE- Medicus Pharma, Lam Research, Applied Digital

Reuters
·
Jan 22

Janux Therapeutics Shares Jump 14.5% Premarket on Global License Deal With Bristol Myers for Cancer Drug Development

THOMSON REUTERS
·
Jan 22

BRIEF-Janux Therapeutics, Bristol Myers Squibb Sign Exclusive Global License To Develop Tumor-Activated Solid Tumor Therapy

Reuters
·
Jan 22

Janux Therapeutics Inc - Co Also Entitled to Tiered Royalties on Global Sales

THOMSON REUTERS
·
Jan 22

Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement With Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors

THOMSON REUTERS
·
Jan 22

Janux Therapeutics Inc - as Part of Collaboration, Co Will Complete Preclinical Development up to Ind Submission

THOMSON REUTERS
·
Jan 22

Janux Therapeutics Inc - as Part of Collaboration, Bristol Will Hold Ind & Be Responsible for Subsequent Development & Global Commercialization

THOMSON REUTERS
·
Jan 22

Janux Therapeutics Inc - to Receive up to $50 Mln Upfront, $800 Mln in Milestones

THOMSON REUTERS
·
Jan 22

Janux Therapeutics: Under Terms, Co Is Eligible to Receive Development, Regulatory & Commercial Milestones up to About $800 Mln in Aggregate

THOMSON REUTERS
·
Jan 22

Janux Therapeutics Cut to Hold From Buy by Clear Street

Dow Jones
·
Jan 20

Janux Therapeutics downgraded to Hold from Buy at Clear Street

TIPRANKS
·
Jan 20

Janux Therapeutics Is Maintained at Overweight by Piper Sandler

Dow Jones
·
Jan 17

Janux Therapeutics price target lowered to $30 from $42 at Piper Sandler

TIPRANKS
·
Jan 16

BofA Adjusts Price Target on Janux Therapeutics to $35 From $49, Maintains Buy Rating

MT Newswires Live
·
Jan 06